TrialBritish journal of pharmacology2017

Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).

Scott P Webster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.